A recent commentary in Nature Medicine addresses emerging reports of T cell malignancies after #CARTcell therapy, overall benefits over potential risks & importance of supporting U.S. FDA long-term follow-up recommendations for treated patients. Read more: ow.ly/tte950RsXBK

#QuoteoftheDay Will you do or don't?
'The difference between perseverance and obstinacy is that one often comes from a strong will, and the other from a strong won't.'
19th Century Cleric, Henry Ward Beecher
h/t Rick Itzkowich

Who has a yearning for food poisoning?
'My rendezvous with the raw milk black market: quick, easy, and unchecked by the #FDA ' statnews.com/2024/05/15/bir… via STAT Nicholas Florko

From the company that brought you Theranos Wellness Centers

From the data available so far, secondary cancers from #CARTCellTherapy seem to be a rare phenomenon, and the benefits of therapy still outweigh the risks in most cases. Penn Medicine - Abramson Cancer Center's Bruce Levine, Ph.D. 🇺🇦 and Marco Ruella discussed with nature. spr.ly/6016jxlB4

Today we celebrate Emily Whitehead Foundation 12 years cancer free 👏, and give our thanks to all patients who have contributed to #CARTCell #immunotherapy development.

STING me! 🐝The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion Penn Medicine Ugur Uslu #CARTCell #immunotherapy

Another view from #ASGCT2024

Congrats Qasim!

1st patient to receive base edited CAR T Cell #immunotherapy

Extraordinary claims - check
Extraordinary evidence - No check
Regulatory compliance - Probably not

Measles is coming back. My sister Marcie isn’t. For every 1,000 people who get #measles , one develops measles encephalitis, which can cause permanent brain damage statnews.com/2024/05/07/mea… via STAT

For the lucky few, hoping for a cure - 12 yo Boy Begins Newly Approved Sickle Cell Gene Therapy. We must innovate to provide better access to #GeneTherapy nytimes.com/2024/05/06/hea…

May 16 IRL in #Philly I'll be at The Future of Life Sciences: Can biotech bounce back? Philadelphia Business Journal #Philly #CelliconValley bizjournals.com/philadelphia/e…

CD19 CAR-T armored with IL18 being studied for CAR-T relapse patients, Penn Medicine trials led by Jakub Svoboda NCT04684563 & NCT05989204
#CARTCell #tcell #tcell rx #immunotherapy BiotechTV AliGorman Brad Loncar biotechtv.com/post/penn-medi…

Great day for a ride in the woods 🚴

Early career star of #CARTCell #TCell #immunotherapy
Sofía Castelli shines on @BiotechTV w AliGorman

Early career star of #CARTCell #TCell #immunotherapy
tatiana blanchard shines on @BiotechTV w AliGorman

The ISCT Expanded Access Working Group is partnering with the NYU Grossman School of Medicine Division of Medical Ethics' Working Group on Compassionate Use & Preapproval Access to present a free webinar on 'Expanded Access 101'.

Register now and join the discussion:
buff.ly/44sd5rB